Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.34 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.34 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | XPO1 | O14980 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650144 | 1.00 | CNR2 (0.42) | CNR2LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL30551454 | 0.93 | CNR2 (0.38) | CNR2LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL828662 | 0.84 | NPC1 (0.42) | LMNASMN1; SMN2ALDH1A1USP30SYK | |
| SCHEMBL25318586 | 0.82 | USP30 (0.38) | CNR2LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12678539 | 0.82 | SSTR4 (0.40) | CNR2SMN1; SMN2ALDH1A1USP30SYK | |
| SCHEMBL29417518 | 0.82 | USP30 (0.39) | CNR2ALDH1A1USP30SYKATR | |
| SCHEMBL25295526 | 0.82 | SSTR4 (0.40) | USP30SYKAAK1PAX8SSTR4 | |
| SCHEMBL29580743 | 0.82 | SSTR4 (0.40) | CNR2SMN1; SMN2ALDH1A1USP30SYK | |
| SCHEMBL13588405 | 0.81 | USP30 (0.38) | SMN1; SMN2ALDH1A1L3MBTL1USP30SYK | |
| SCHEMBL3937375 | 0.81 | CCR1 (0.41) | LMNAUSP30AAK1PAX8SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| WO-2022118016-A2 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-06-09 | — | — | WO | disclosed |
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-9248199-B2 | 1:1 adducts of sickle hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2970308-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | Global Blood Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015116061-A1 | 1:1 ADDUCTS OF SICKLE HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-08-06 | — | — | WO | disclosed |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2015-07-30 | — | — | US | disclosed |
| US-20150209443-A1 | 1:1 ADDUCTS OF SICKLE HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| WO-2014150276-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20090054428-A1 | NOVEL PYRIMIDINE DERIVATIVES 965 | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| WO-2009010794-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174654-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CNR2 2937/4885LMNA 823/4885SMN1; SMN2 1176/4885 |
| US-20150209443-A1 | 1:1 ADDUCTS OF SICKLE HEMOGLOBIN | HBG1, HBB, HBG2 | CNR2 4315/4885LMNA 886/4885SMN1; SMN2 97/4885 |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CNR2 2937/4885LMNA 823/4885SMN1; SMN2 1176/4885 |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | NTRK2, MUSK, NTRK3 | CNR2 19/4885LMNA 1449/4885SMN1; SMN2 833/4885 |
| US-20160046613-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | CNR2 2937/4885LMNA 823/4885SMN1; SMN2 1176/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | CNR2 405/4885LMNA 823/4885SMN1; SMN2 1226/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CNR2 2937/4885LMNA 823/4885SMN1; SMN2 1176/4885 |
| US-20090054428-A1 | NOVEL PYRIMIDINE DERIVATIVES 965 | EPHB4, EPHB1, EPHB3 | CNR2 1870/4885LMNA 4211/4885SMN1; SMN2 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.